查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403452

到 2030 年结核病诊断市场预测：按产品类型、测试类型、阶段、最终用户和地区进行的全球分析

Tuberculosis Diagnostics Market Forecasts to 2030 - Global Analysis By Product Type, Test Type, Disease Stage, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球结核病诊断市场规模为 20.7 亿美元，预计到 2030 年将达到 34.6 亿美元，预测期内复合年增长率为 7.6%。

结核病是一种由结核分枝桿菌引起的传染性疾病，主要攻击患者的肺部、脊椎和大脑。结核病诊断客观、准确地辨识结核感染。结核病诊断有助于区分结核病与其他症状相似的呼吸道疾病，减少误诊和不必要的治疗。

根据世界卫生组织《2022年全球结核病报告》，2021年全球约有1,060万人感染结核病，比2020年报告的1,010万人增加了4.5%。

抗药性结核病

多重抗药性结核病 (MDR-TB) 和广泛抗药性结核病 (XDR-TB) 等抗药性结核菌株的出现，需要准确、快速的诊断检测。抗药性结核分枝桿菌对标准第一线抗结核药物没有反应，因此检测和适当的治疗至关重要。使用传统诊断方法难以识别抗药性结核分枝桿菌，可能会导致治疗延迟或无效、感染传播增加以及患者预后不佳。因此，对能够准确检测抗药性结核病的先进诊断方法的需求不断增长。

高成本

与痰液涂片显微镜等传统方法相比，分子和基因型测试等先进诊断技术通常价格昂贵。这些测试的成本不仅包括检测套组，还包括执行这些测试所需的设备、实验室基础设施和技术人员。因此，高成本可能会阻碍医疗保健提供者实施更先进、更精确的诊断技术，从而阻碍市场成长。

先进的诊断技术

聚合酶链反应（PCR）和核酸增幅检查（NAAT）等分子技术的使用提高了结核病的检测灵敏度，甚至可以诊断细菌计数较低的病例。此外，即时检测的改进使诊断更接近患者。这在资源有限的环境中特别有利，因为它减少了从治疗开始到结果的时间。因此，这些先进的诊断技术将加速市场成长。

柱头

对传播方式的误解、对感染的恐惧以及与贫困和边缘群体的联繫是导致结核病耻辱的一些因素。然而，这种耻辱可能导致个人不愿透露症状、寻求医疗保健和接受结核病诊断检测。由于担心社会排斥、歧视和不利的社会观念，人们可能无法接受结核病诊断服务。这可能会延误诊断并导致疾病传播。这些因素都阻碍了市场需求。

COVID-19 的影响

COVID-19大流行对结核病诊断市场产生了重大影响。虽然它最初扰乱了医疗保健系统并转移了结核病诊断的资源，但它也凸显了强大的诊断基础设施的重要性。随着大流行的消退，人们将越来越认识到加强医疗保健系统的必要性，这可能对结核病诊断有长期好处。此外，COVID-19 可能加速了远端医疗和数位医疗的进步，这可能会提高我们诊断结核病的能力。

诊断测试领域预计将在预测期内成为最大的领域

诊断测试方法部分估计占最大份额。世界各地的大多数医院和诊所都进行基于培养的测试以及涂片显微镜检查。这使得它成为无法获得更先进诊断技术的患者诊断结核病的可行选择。此外，涂片显微镜检查和基于培养的测试仍然是诊断结核病最准确的测试，儘管核酸增幅检查(NAAT) 等更新的测试正变得越来越广泛。

痰液涂片显微镜检查领域预计在预测期内复合年增长率最高。

痰液涂片显微镜领域预计在预测期内将出现良好的成长。痰液涂片镜是一种简单且经济有效的技术，用于检测痰液样本中的抗酸桿菌（AFB），有助于诊断肺结核。痰液涂片显微镜检查不需要复杂的测试基础设施或昂贵的设备，因此可以在资源有限的环境中广泛使用。此外，快速的结果使医护人员能够快速开始结核病治疗，减少感染并改善患者的治疗结果。

比最大的地区

亚太地区由于疾病的负担高且扩散迅速，在市场上占据主导地位并占据最大的市场占有率份额。该地区多个国家结核病发病率上升是推动市场收益增加的主要因素之一。此外，该地区的高死亡率和低人类发展指数是支撑市场收益成长的关键因素。该地区受影响的国家包括孟加拉、中国、印度、印尼、巴基斯坦和菲律宾。

复合年增长率最高的地区：

由于成人和儿童结核病患者病率上升，预计北美在预测期内将出现有益的增长。该地区的医学研究机构正在越来越多地取得与病原体特异性代谢途径相关的有价值的发现。这可能是专注于检测病原体免疫反应、细菌生长或细菌核酸扩增的现有技术的替代方案。此外，人工智慧与奈米技术的结合可以大大帮助改善北美患者的结核病诊断流程。

提供免费客製化：

订阅此报告的客户将收到以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球结核病诊断市场：依产品类型

  • 痰液涂片镜检
  • 培养诊断
  • 快速分子诊断
  • 其他产品类型

第六章全球结核病诊断市场：依测试类型

  • 检测潜伏感染
  • 射线照相
  • 核酸检测
  • 噬菌体测定
  • 诊断测试方法
  • 抗药性检测
  • 细胞激素检测分析
  • 其他测试类型

第七章全球结核病诊断市场：依阶段

  • 活动性结核病
  • 潜伏性结核病

第八章全球结核病诊断市场：依最终用户分类

  • 医生办公室
  • 医院和诊断实验室
  • 参考实验室
  • 学术研究设施
  • 其他最终用户

第九章全球结核病诊断市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Becton Dickinson and Company
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Oxford Immunotec Ltd.
  • Hoffmann-La Roche Ltd.
  • Hologic Inc.
  • BioMerieux SA
  • Akonni Biosystems Inc.
  • Cepheid Inc.
  • Alere Inc.
  • PAR Pharmaceuticals
  • Hain Life Science.
  • Lionex GmbH
Product Code: SMRC24677

According to Stratistics MRC, the Global Tuberculosis Diagnostics Market is accounted for $2.07 billion in 2023 and is expected to reach $3.46 billion by 2030 growing at a CAGR of 7.6% during the forecast period. Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis and it mainly attacks the lungs, spine, and brain of the patients. Tuberculosis diagnostics provide objective and precise identification of TB infection. They help differentiate TB from other respiratory diseases with similar symptoms, reducing misdiagnosis and unnecessary treatments.

According to the WHO Global Tuberculosis report 2022, in 2021, approximately 10.6 million individuals fell ill with tuberculosis globally, representing 4.5% rise from 10.1 million cases reported in 2020.

Market Dynamics:

Driver:

Drug-resistant TB

The emergence of drug-resistant strains, such as multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), has created a need for accurate and rapid diagnostic tests. Drug-resistant TB strains do not respond to the standard first-line anti TB medications, making their detection and appropriate treatment critical. Traditional diagnostic methods may not be effective in identifying drug-resistant strains, leading to delayed or ineffective treatment, increased transmission, and poor patient outcomes. As a result, there is a growing demand for advanced diagnostics that can accurately detect drug-resistant TB.

Restraint:

High cost

Advanced diagnostic technologies, such as molecular tests and genotypic assays, often come with a higher price tag compared to traditional methods like sputum smear microscopy. The cost of these tests includes not only the test kits but also the equipment, laboratory infrastructure, and skilled personnel required for their implementation. Therefore, high costs may deter healthcare providers from implementing more advanced and precise diagnostic techniques, impeding the growth of the market.

Opportunity:

Advanced diagnostic technologies

The utilization of molecular techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), allows for the detection of TB with enhanced sensitivity, enabling diagnosis even in cases with low bacterial loads. Additionally, improvements in point-of-care testing bring diagnostics closer to the patient. This is especially advantageous in settings with limited resources because it shortens the time between starting treatment and receiving results. Therefore, these advanced diagnostic technologies accelerate market growth.

Threat:

Stigma

Misconceptions regarding the mode of transmission, fear of infection, and associations with poverty or marginalized groups are some of the factors that contribute to the stigma surrounding tuberculosis. However, this stigma can lead to reluctance among individuals to disclose their symptoms, seek healthcare, or undergo TB diagnostic testing. People may be unable to receive TB diagnostic services because of fear of social exclusion, discrimination, or unfavourable societal perceptions. This can postpone diagnosis and contribute to the disease's spread. These factors hamper market demand.

COVID-19 Impact

The COVID-19 pandemic has had a significant impact on the tuberculosis diagnostics market. While it initially disrupted healthcare systems, diverting resources away from TB diagnostics, it also highlighted the importance of robust diagnostic infrastructure. Long-term benefits for TB diagnostics could result from increased awareness of the need for strengthening healthcare systems as the pandemic fades. Furthermore, COVID-19 may have accelerated advancements in telemedicine and digital health, which could improve the capacity for tuberculosis diagnosis.

The diagnostic laboratory methods segment is expected to be the largest during the forecast period

The diagnostic laboratory methods segment is estimated to hold the largest share. Most hospitals and clinics globally provide culture-based tests as well as smear microscopy. Due to this, they are a viable choice for tuberculosis diagnosis for patients who might not have access to more sophisticated diagnostic procedures. Moreover, while newer tests, such as nucleic acid amplification tests (NAATs), are becoming more widely available, smear microscopy and culture-based tests are still considered to be the most accurate tests for diagnosing tuberculosis.

The sputum smear microscopy segment is expected to have the highest CAGR during the forecast period

The sputum smear microscopy segment is anticipated to have lucrative growth during the forecast period. It is a simple and cost-effective technique used to detect acid-fast bacilli (AFB) in sputum samples, aiding in the diagnosis of pulmonary TB. Sputum smear microscopy is widely available, even in resource-limited settings, as it does not require sophisticated laboratory infrastructure or expensive equipment. Moreover, it provides rapid results, enabling healthcare providers to initiate TB treatment promptly, reducing transmission, and improving patient outcomes.

Region with largest share:

Asia Pacific dominated the market and accounted for the largest market share due to its high burden as well as the rapid proliferation of this disease. The rising rates of tuberculosis in several of the countries in this region are one of the primary drivers of the increase in market revenue. Furthermore, the high mortality rate and low human development index in this region are important factors that support the growth in market revenue. Bangladesh, China, India, Indonesia, Pakistan, and the Philippines are among the affected nations in this region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, owing to the rising prevalence of tuberculosis among adults and children. Medical research institutes in this region are discovering an increasing number of benefits associated with pathogen-specific metabolic pathways. This could serve as a substitute for the existing techniques that focus on the detection of pathogen immune responses, bacterial growth, or bacterial nucleic acid amplification. Additionally, AI and nanotechnology combined significantly aid in improving the tuberculosis diagnosis process among patients in North America.

Key players in the market:

Some of the key players in the Tuberculosis Diagnostics Market include Becton Dickinson and Company, Qiagen NV, Thermo Fisher Scientific Inc., Oxford Immunotec Ltd., Hoffmann-La Roche Ltd., Hologic Inc., BioMerieux SA, Akonni Biosystems Inc., Cepheid Inc., Alere Inc., PAR Pharmaceuticals, Hain Life Science and Lionex GmbH.

Key Developments:

In February 2022 - QIAGEN announced that its QuantiFERON tuberculosis testing solution received the approval of the fourth generation of a modern gold standard test in China.

In March 2022, Thermo Fisher Scientific Inc. launched the SeqStudio Flex Series Genetic Analyzer for research & development of infectious disease detection, which is expected to expand the company's product portfolio in the market.

Product Types Covered:

  • Sputum Smear Microscopy
  • Culture-Based Diagnostics
  • Rapid Molecular Diagnostics
  • Other Product Types

Test Types Covered:

  • Detection of Latent Infection
  • Radiographic Method
  • Nucleic Acid Testing
  • Phage Assay
  • Diagnostic Laboratory Methods
  • Detection of Drug Resistance
  • Cytokine Detection Assay
  • Other Test Types

Disease Stages Covered:

  • Active Tuberculosis
  • Latent Tuberculosis

End Users Covered:

  • Physician's Office Laboratories
  • Hospitals and Diagnostic Laboratories
  • Reference Laboratories
  • Academics and Research Facilities
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Tuberculosis Diagnostics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Sputum Smear Microscopy
  • 5.3 Culture-Based Diagnostics
  • 5.4 Rapid Molecular Diagnostics
  • 5.5 Other Product Types

6 Global Tuberculosis Diagnostics Market, By Test Type

  • 6.1 Introduction
  • 6.2 Detection of Latent Infection
  • 6.3 Radiographic Method
  • 6.4 Nucleic Acid Testing
  • 6.5 Phage Assay
  • 6.6 Diagnostic Laboratory Methods
  • 6.7 Detection of Drug Resistance
  • 6.8 Cytokine Detection Assay
  • 6.9 Other Test Types

7 Global Tuberculosis Diagnostics Market, By Disease Stage

  • 7.1 Introduction
  • 7.2 Active Tuberculosis
  • 7.3 Latent Tuberculosis

8 Global Tuberculosis Diagnostics Market, By End User

  • 8.1 Introduction
  • 8.2 Physician's Office Laboratories
  • 8.3 Hospitals and Diagnostic Laboratories
  • 8.4 Reference Laboratories
  • 8.5 Academics and Research Facilities
  • 8.6 Other End Users

9 Global Tuberculosis Diagnostics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Becton Dickinson and Company
  • 11.2 Qiagen NV
  • 11.3 Thermo Fisher Scientific Inc.
  • 11.4 Oxford Immunotec Ltd.
  • 11.5 Hoffmann-La Roche Ltd.
  • 11.6 Hologic Inc.
  • 11.7 BioMerieux SA
  • 11.8 Akonni Biosystems Inc.
  • 11.9 Cepheid Inc.
  • 11.10 Alere Inc.
  • 11.11 PAR Pharmaceuticals
  • 11.12 Hain Life Science.
  • 11.13 Lionex GmbH

List of Tables

  • Table 1 Global Tuberculosis Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 4 Global Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 5 Global Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 6 Global Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 7 Global Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 8 Global Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 9 Global Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 10 Global Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 11 Global Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 12 Global Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 13 Global Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 14 Global Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 15 Global Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 16 Global Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 17 Global Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 18 Global Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 19 Global Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 20 Global Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 21 Global Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 22 Global Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 23 Global Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 24 Global Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 25 North America Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 North America Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 27 North America Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 28 North America Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 29 North America Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 30 North America Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 31 North America Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 32 North America Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 33 North America Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 34 North America Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 35 North America Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 36 North America Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 37 North America Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 38 North America Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 39 North America Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 40 North America Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 41 North America Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 42 North America Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 43 North America Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 44 North America Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 45 North America Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 46 North America Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 47 North America Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 48 North America Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 49 Europe Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 Europe Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 51 Europe Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 52 Europe Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 53 Europe Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 54 Europe Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 55 Europe Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 56 Europe Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 57 Europe Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 58 Europe Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 59 Europe Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 60 Europe Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 61 Europe Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 62 Europe Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 63 Europe Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 64 Europe Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 65 Europe Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 66 Europe Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 67 Europe Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 68 Europe Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 69 Europe Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 70 Europe Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 71 Europe Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 72 Europe Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 73 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 74 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 75 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 76 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 77 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 78 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 79 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 80 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 81 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 82 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 83 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 84 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 85 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 86 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 87 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 88 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 89 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 90 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 91 Asia Pacific Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 92 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 93 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 94 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 95 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 96 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 97 South America Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 98 South America Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 99 South America Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 100 South America Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 101 South America Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 102 South America Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 103 South America Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 104 South America Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 105 South America Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 106 South America Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 107 South America Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 108 South America Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 109 South America Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 110 South America Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 111 South America Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 112 South America Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 113 South America Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 114 South America Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 115 South America Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 116 South America Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 117 South America Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 118 South America Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 119 South America Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 120 South America Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 121 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 122 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 123 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
  • Table 124 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
  • Table 125 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
  • Table 126 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 127 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 128 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
  • Table 129 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
  • Table 130 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
  • Table 131 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
  • Table 132 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
  • Table 133 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
  • Table 134 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
  • Table 135 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 136 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
  • Table 137 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
  • Table 138 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
  • Table 139 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 140 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
  • Table 141 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
  • Table 142 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 143 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
  • Table 144 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)